Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Zender

Showing results (141-150 of 192) with videos related to

Pageof 20
Sort By:
Neuro-Oncology Advances|November 2, 2020
Experimental glioma with high bHLH expression harbor increased replicative stress and are sensitive toward ATR inhibitionMarilin Sophia Koch, Stefan Czemmel, Felix Lennartz, et al.
Journal of Medicinal Chemistry|February 15, 2022
Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) InhibitorRicardo A M Serafim, André da Silva Santiago, Martin P Schwalm, et al.
Carcinogenesis|February 13, 2019
The administration route of tumor-antigen-specific T-helper cells differentially modulates the tumor microenvironment and senescenceChristoph M Griessinger, Andreas M Schmid, Dominik Sonanini, et al.
Nature|July 22, 2014
Activation and repression by oncogenic MYC shape tumour-specific gene expression profilesSusanne Walz, Francesca Lorenzin, Jennifer Morton, et al.
Nature Medicine|May 24, 2016
A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancerDaniel Dauch, Ramona Rudalska, Giacomo Cossa, et al.
Nature Communications|May 16, 2019
Nucleoporin Nup155 is part of the p53 network in liver cancerKerstin Holzer, Alessandro Ori, Amy Cooke, et al.
Cancers|October 20, 2020
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF TrialIan Chau, Nicolas Penel, Andres O Soriano, et al.
Cancer Immunology, Immunotherapy : CII|May 15, 2025
Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescencePujan Engels, Andras Szolek, Sebastian Hörner, et al.
Cell|June 4, 2016
p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver CancerDarjus F Tschaharganeh, Wen Xue, Diego F Calvisi, et al.
Theranostics|May 22, 2023
<i>In vivo</i> imaging of CD8<sup>+</sup> T cells in metastatic cancer patients: first clinical experience with simultaneous [<sup>89</sup>Zr]Zr-Df-IAB22M2C PET/MRIJohannes Schwenck, Dominik Sonanini, Dominik Seyfried, et al.
Pageof 20

Showing results (141-150 of 192) with videos related to

Sort By:
Pageof 20
Neuro-Oncology Advances|November 2, 2020
Experimental glioma with high bHLH expression harbor increased replicative stress and are sensitive toward ATR inhibitionMarilin Sophia Koch, Stefan Czemmel, Felix Lennartz, et al.
Journal of Medicinal Chemistry|February 15, 2022
Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) InhibitorRicardo A M Serafim, André da Silva Santiago, Martin P Schwalm, et al.
Carcinogenesis|February 13, 2019
The administration route of tumor-antigen-specific T-helper cells differentially modulates the tumor microenvironment and senescenceChristoph M Griessinger, Andreas M Schmid, Dominik Sonanini, et al.
Nature|July 22, 2014
Activation and repression by oncogenic MYC shape tumour-specific gene expression profilesSusanne Walz, Francesca Lorenzin, Jennifer Morton, et al.
Nature Medicine|May 24, 2016
A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancerDaniel Dauch, Ramona Rudalska, Giacomo Cossa, et al.
Nature Communications|May 16, 2019
Nucleoporin Nup155 is part of the p53 network in liver cancerKerstin Holzer, Alessandro Ori, Amy Cooke, et al.
Cancers|October 20, 2020
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF TrialIan Chau, Nicolas Penel, Andres O Soriano, et al.
Cancer Immunology, Immunotherapy : CII|May 15, 2025
Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescencePujan Engels, Andras Szolek, Sebastian Hörner, et al.
Cell|June 4, 2016
p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver CancerDarjus F Tschaharganeh, Wen Xue, Diego F Calvisi, et al.
Theranostics|May 22, 2023
<i>In vivo</i> imaging of CD8<sup>+</sup> T cells in metastatic cancer patients: first clinical experience with simultaneous [<sup>89</sup>Zr]Zr-Df-IAB22M2C PET/MRIJohannes Schwenck, Dominik Sonanini, Dominik Seyfried, et al.
Pageof 20